Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

A number of other brokerages have also issued reports on ALXN. Barclays PLC restated an “overweight” rating and issued a $155.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Deutsche Bank AG cut their target price on shares of Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Raymond James Financial, Inc. restated a “strong-buy” rating and issued a $176.00 target price on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 9th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $158.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Finally, Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 18th. Eight investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $161.38.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded up 2.49% during trading on Tuesday, hitting $119.05. The company’s stock had a trading volume of 3,592,187 shares. The firm’s 50 day moving average price is $112.77 and its 200-day moving average price is $122.35. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $145.41. The company has a market cap of $26.73 billion, a PE ratio of 56.72 and a beta of 1.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.33. The business had revenue of $870 million for the quarter, compared to analyst estimates of $826.63 million. Alexion Pharmaceuticals had a net margin of 14.52% and a return on equity of 11.72%. The company’s revenue for the quarter was up 24.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.11 EPS. On average, analysts predict that Alexion Pharmaceuticals will post $5.31 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/06/20/alexion-pharmaceuticals-inc-alxn-upgraded-to-hold-at-bidaskclub.html.

In other news, Director Bros. Advisors Lp Baker bought 660,779 shares of the firm’s stock in a transaction on Thursday, June 15th. The stock was purchased at an average price of $117.33 per share, for a total transaction of $77,529,200.07. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Ludwig Hantson bought 10,000 shares of the firm’s stock in a transaction on Wednesday, June 14th. The stock was purchased at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the transaction, the chief executive officer now owns 38,725 shares in the company, valued at approximately $4,519,982. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 2,019,734 shares of company stock valued at $235,606,846. 4.35% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ALXN. Russell Investments Group Ltd. bought a new position in Alexion Pharmaceuticals during the fourth quarter valued at about $3,024,000. Private Advisor Group LLC bought a new position in Alexion Pharmaceuticals during the fourth quarter valued at about $231,000. Dimensional Fund Advisors LP boosted its position in Alexion Pharmaceuticals by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 307,780 shares of the biopharmaceutical company’s stock valued at $37,660,000 after buying an additional 1,385 shares during the period. Credit Agricole S A boosted its position in Alexion Pharmaceuticals by 24.7% in the fourth quarter. Credit Agricole S A now owns 62,642 shares of the biopharmaceutical company’s stock valued at $7,665,000 after buying an additional 12,410 shares during the period. Finally, Flinton Capital Management LLC bought a new position in Alexion Pharmaceuticals during the fourth quarter valued at about $562,000. Institutional investors and hedge funds own 94.40% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.